Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Aug 4;10(1):13160.
doi: 10.1038/s41598-020-70207-7.

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC

Pengfei Cui #  1   2 , Ruixin Li #  2 , Ziwei Huang #  2   3 , Zhaozhen Wu  2   3 , Haitao Tao  2 , Sujie Zhang  2 , Yi Hu  4   5   6
Affiliations
Comparative Study

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC

Pengfei Cui et al. Sci Rep. .

Abstract

The efficacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients with recurrent or advanced non-small cell lung cancer (NSCLC) in a real-world setting. This study included patients with recurrent or advanced NSCLC diagnosed between September 1, 2015 and August 31, 2019, who were treated with programmed cell death 1 (PD-1) inhibitors at the Cancer Center of the Chinese People's Liberation Army. PFS was estimated for each treatment group using Kaplan-Meier curves and log-rank tests. The multivariate analysis of PFS was performed with Cox proportional hazards regression models. A total of 255 patients with advanced or recurrent NSCLC treated with PD-1 inhibitors were identified. The ORR was significantly higher in the pembrolizumab group than in the nivolumab group, while PFS was not significantly different between the two groups. Subgroup analysis showed that the ORR was significantly higher for pembrolizumab than for nivolumab in patients in the first-line therapy subgroup and in those in the combination therapy as first-line therapy subgroup. Survival analysis of patients receiving combination therapy as second- or further-line therapy showed that nivolumab had better efficacy than pembrolizumab. However, the multivariate analysis revealed no significant difference in PFS between patients treated with pembrolizumab and those treated with nivolumab regardless of the subgroup. In our study, no significant difference in PFS was noted between patients treated with pembrolizumab and those treated with nivolumab in various clinical settings. This supports the current practice of choosing either pembrolizumab or nivolumab based on patient preferences.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Progression-free survival of patients with NSCLC treated with pembrolizumab or nivolumab.
Figure 2
Figure 2
Progression-free survival for patients receiving PD-1 inhibitors monotherapy in the first line therapy.
Figure 3
Figure 3
Progression-free survival for patients receiving combined therapy in the first line therapy.
Figure 4
Figure 4
Progression-free survival of for patients receiving PD-1 inhibitors monotherapy in the second line therapy.
Figure 5
Figure 5
Progression-free survival of for patients receiving combined therapy in the second line therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355. doi: 10.1126/science.aar4060. - DOI - PMC - PubMed
    1. Tang J, et al. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 2018;17:854–855. doi: 10.1038/nrd.2018.210. - DOI - PubMed
    1. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015;373:1627–1639. doi: 10.1056/NEJMoa1507643. - DOI - PMC - PubMed
    1. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015;372:2018–2028. doi: 10.1056/NEJMoa1501824. - DOI - PubMed
    1. Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin. Oncol. 2017;44:136–140. doi: 10.1053/j.seminoncol.2017.06.002. - DOI - PMC - PubMed

Publication types

MeSH terms